KEY TAKEAWAYS
- The study aimed to investigate real-world outcomes of post-cBTKi treatment in patients with r/r MCL for comprehensive understanding.
- The results revealed the critical importance of ongoing development of novel therapeutics to address unmet patient needs.
Covalent Bruton’s tyrosine kinase inhibitors (cBTKis) are standard treatment for relapsed/refractory mantle cell lymphoma (r/r MCL), but limited response duration and resistance are observed.
Patrick Squires and the team aimed to assess post-cBTKi clinical and economic outcomes in patients with r/r MCL, addressing existing evidence gaps.
Researchers utilized 2010-2019 U.S. Medicare claims to identify elderly patients (aged ≥66 years) newly diagnosed with MCL. These patients received third-line (3L) treatment and previously demonstrated evidence of cBTKi use. Outcomes evaluated ≥12 months post third-line treatment initiation included treatment patterns, healthcare resource utilization, costs, and overall survival related to both all-cause and mantle cell lymphoma-specific factors.
About 230 elderly patients with r/r MCL who underwent 3L treatment revealed that all had previously been exposed to cBTKis in earlier therapy regimens. Their mean age was 75.0, with 21.7% aged over 80 years, and the majority were male (67.4%) and White (93.9%).
Among the common 3L treatments administered, chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%) were prominent. A quarter of patients (25.7%) received a cBTKi, predominantly ibrutinib (17.8%) and acalabrutinib (7.8%).
The overall survival post-3L treatment initiation was notably low, with a median of 9.4 months and a 1-year survival rate of 43.7%. Patients exhibited elevated healthcare resource utilization, with 73.6% experiencing hospitalization, and incurred substantial costs, averaging $145,726 within the 12 months following 3L initiation.
The study concluded that within this patient subpopulation, a significant unmet need persists, underscoring the critical importance of continued advancement in the development of novel therapeutics.
This study was supported by Bristol Myers Squibb.
Squires P, Puckett J, Ryland KE, et al. (2024). “Real-world Treatment Patterns, Survival, and Economic Burden among Elderly MCL Patients Previously Treated with cBTKis.” DOI: https://doi.org/10.1016/j.clml.2024.05.023
